Owl Therapeutics, LLC, a wholly-owned subsidiary of Gryphon Bio, Inc., is an early-stage company created to develop diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health.
First-In-Class, Best-In-Class Therapeutics for Traumatic Brain Injury (TBI) & Brain Health
OWL-1023 is a therapeutic monoclonal antibody to accelerate clearance of brain cell debris.
OWL-4130 is a therapeutic fusion protein to limit inflammation in the brain.
OWL-1975 is a small molecule therapeutic to rescue post-traumatic headache.